Chargement en cours...
Clinical and comparative utility of afatinib in non-small cell lung cancer
The first targeted agents approved for non-small cell lung cancer (NSCLC) treatment, the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib, have an impressive activity in the presence of activating mutations of the EGFR gene. However, all patients deve...
Enregistré dans:
| Auteurs principaux: | , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Dove Medical Press
2014
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4003149/ https://ncbi.nlm.nih.gov/pubmed/24790411 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/BTT.S40567 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|